A rapid, speci�c, and accurate isocratic HPLC method was developed and validated for the assay of quetiapine fumarate in pharmaceutical dosage forms. e assay involved an isocratic-elution of quetiapine fumarate in Grace C18 column using mobilephase composition of 0.1% ortho phosphoric acid with triethyl amine as modi�er buffer and acetonitrile in the ratio of 50 : 50 (v/v).e wavelength of detection is 294 nm. e method showed good linearity in the range of 2.0-50.2 × 10 −3 g/Lt. e runtime of the method is 5 mins. e developed method was applied to directly and easily analyse of the pharmaceutical tablet preparations. e percentage recoveries were near 100% for given methods. e method was completely validated and proven to be rugged. e excipients did not interfere in the analysis. e results showed that this method can be used for rapid determination of quetiapine fumarate in pharmaceutical tablet with precision, accuracy, and speci�city.
Introduction
Quetiapine fumarate ( Figure 1 )-chemically known as {2-(2-(4-dibenzo [1, 4] thiazepine-11-yl-1-piperazinyl) ethoxyethanol, fumaric acid (1 : 2 salt; formula C 29 H 33 N 3 O 10 S), molecular weight: 615.66-a dibenzothiazepine derivative, is one of the most recent antipsychotic drugs. An oral antipsychotic drug that acts as an antagonist of multiple neurotransmitters including serotonin and norepinephrine is used in the treatment of schizophrenia. It is a selective monoaminergic antagonist with high affity for the serotonin type 2 (5HT 2 ) and dopamine type 2 (D 2 ) receptors. QTF belongs to the same family as clozapine and olanzapine, which are classi�ed as a typical antipsychotic and do not cause major extrapyramidal side effects. e generic name of quetiapine hemifumarate is Seroquel; it is prescribed for the treatment of schizophrenia, a mental disorder marked by delusions (false beliefs), hallucinations, disrupted thinking, and loss of contact with reality. It is also used for the shortterm treatment of mania associated with bipolar disorder. Seroquel is the �rst in a new class of antipsychotic medications. Researchers believe that it works by diminishing the action of dopamine and serotonin, two of the brain's chief chemical messengers. It is white or almost white powder, moderately soluble in water and soluble in methanol and 0.1 N HCl. It is available in tablets form in dosage level of 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg. Maximum daily dosage is 800 mg in adults. is drug is rapidly absorbed aer oral administration with peak plasma concentration attained within 1.50 hrs. Bioavailability of tablet formulation is 100% relative to an oral solution, which may be marginally affected by food. Plasma protein binding of quetiapine is 83%. e drug is extensively metabolites, principally through CYP3A4. e drug is having half-life period of approximately 6 hours.
Several methods have been reported for the quantitative determination of quetiapine in bulk, and pharmaceutical and biological samples. ese methods include UV-Visible spectrophotometric [1] [2] [3] , UV-derivative and extraction-free methods [4] , HPTLC [5] , Capillary zone electrophoretic method [6] , HPLC-UV-detector [7] [8] [9] [10] [11] , HPLC with solidphase extraction [12] , UPLC with mass-spectrophotometer detector [13] , HPLC with column switching method [14] , gas-chromatography-liquid chromatography-mass spectrophotometry [15] , and hyphenated techniques such as LC-MS [16] , HPLC-electrospray mass ionization mass spectrometry [17], HPLC-Tandem-mass spectropmetry [18] , and HPLC-MS-MS method [19] . Literature survey revealed that only few internal standard methods have been reported for the quanti�cation of quetiapine fumarate in bulk and pharmaceutical formulations. A comparison of various methods with present study has been tabulated in (Table 11) . So, the authors have developed a new internal standard method which is more rugged, precise, and accurate.
Experimental

Chemicals and Reagents.
Quetiapine fumarate (99.92%) was gi sample from corpuscle research solutions and lamotrogine (99.89% pure, internal standard was procured from corpuscle research solutions. Ascetonitrile (HPLC grade) was obtained from Qualigens �ne chemicals. Milli-Q water was purchased from Ranbaxy �ne chemicals limited (RFCL). All chemicals used were of analytical grade.
2.2.
Instrumentation. e HPLC system consisted of a Shimadzu Class VP Binary pump LC-10Atvp, SIL-10Dvp Autosampler, CTO-10Avp column temperature Oven, PDA-UV Detector. All the components of the system are controlled using SCL-10Avp System Controller. Data acquisitions were done using LC-solution soware. e mobile phase consists of 50 : 50 (v/v) of acetonitrile and 0.1% orthophosphoric acid with added tri-ethyl amine as modi�er, operated on isocratic mode. Analysis was carried out at 294 nm. e chromatographic separation of quetiapine fumarate (drug) and lamotrogine (ISTD) was carried out using GRACE Genesis C18 column (50 × 4.6 mm ID, 3 μm). e �ow rate is 0.6 mL/min.e injection volume is 10 μL. Diluents consists of 50 : 50 (v/v) methanol and 0.1% orthophosphoric acid. 
Preparation of Solutions
Sample Preparation.
Commercially available tablets of quetiapine fumarate are taken from two different brands and tested for assay. Twenty tablets of each brand are taken and crushed to powder. A powder equivalent to 50 × 10 −3 g of quetiapine fumarate is taken and transferred into a stoppered conical �ask to which 25 mL of methanol is added. e contents are transferred into a stoppered �ask and shaken for 20 mins to extract the drug. Contents are carefully transferred into a centrifuge tube and centrifuged for 4000 rpm for 20 mins. e supernatant liquid is taken and diluted with diluents, to obtain approximately �nal concentration of 25 × 10 −3 g/Lt. is sample is analyzed in triplicate. e accuracy and concentration are determined using regression equation.
Method Validation
System Suitability.
System suitability is an integral part of the LC method. ey are used to verify that resolution. Reproducibility is adequate. is is based on the concept that equipment, electronics, analytical operations, analytical operator, and sample constitute an integral system that can be evaluated as such. e system suitability was assessed by six replicate analysis of the drug at a concentration of 15.06 × 10 −3 g/Lt. e acceptance criterion is ±1% for the percent coefficient of the variation for the peak area and retention times for both drug and internal standard. e parameters which we have evaluated are USP theoretical plates, USP tailing factor, and USP resolution. e following formulas have been used for the calculation of Figure 2 ) and quantization (LOQ) ( Figure 3 ) were estimated from both linearity calibration curve method and signal-to-noise ratio method. e detection limit was de�ned as the lowest concentration level resulting in a peak area of three-times baseline noise. e quantization limit was de�ned as the lowest concentration level that provided a peak area with signal-to-noise ratio higher than 10, with precision (%CV) and accuracy with (±)10%. 2.01 to 50.20 μg/mL. e peak area ratio of the drug to the internal standard was evaluated by linearity graph. e linearity was evaluated by linear regression analysis, which was calculated by least square method. It is depicted in (Figure 4 ).
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Accuracy and Precision.
Accuracy of assay method was determined for both intraday and interday variations using triplicate analysis of the QC samples. Precision of the assay was determined by repeatability (intra-day) and intermediate precision (interday) . Repeatability refers to the use of the analytical procedure within the laboratory over the shorter period of the time that was evaluated by assaying the QC samples during the same day. Intermediate precision was assessed by comparing the assays on different days (3 days).
2.4.�.
S�e�i��ity. Speci�city of the method was determined by injecting 3 samples:
(1) blank sample ( A less than 20% interference of the peak area at the retention time of the drug in the blank sample and zero blank samples are taken as acceptance criteria for the analyte. e interference of the internal standard the peak area at the retention time of the internal standard must be less than 5% in the blank sample. Speci�city is also observed in the degradation study of the drug. None of the degraded products must interfere with the quanti�cation of the drug.
2.4.6. Stability. e stability of the drug is determined by using QC samples kept at room temperature up to 12 hours and then analyzing them. Further, autosampler stability for up to 24 hrs and long-term stability unto 30 days were also established.
Stress
Testing. Stress testing of the drug substance can help identify the likely degradation products; we can also validate the stability and speci�city of the analytical procedure. For degradation study 10 mg of quetiapine fumarate was accurately weighed and transferred to a 10 mL volumetric �ask (step 1). 6 sets of 1 mL aliquots were taken and transferred into ria vials. Set 1 is le untreated, to the sample of set 2, 100 × 10 −6 of 0.1 N NaOH, for set 3, 100 × 10 −6 L of 0.1 N HCL, for set 4, 100 × 10 −6 L of 3% H 2 O 2 were added; these sets of samples were placed in a water bath maintained at 60
∘ C for about 24 hrs; for set 5, sample is exposed to UV lamp at 294 nm for about 24 hrs; for set 6, sample is kept in a oven at temperature of about 105 ∘ C, for about 24 hrs. All the samples are kept under stress condition for 24 hrs before �nal analysis. Samples are then taken; 50 × 10 −6 L of internal standard is added and diluted with diluents solution to obtain a �nal concentration of 25.10 × 10 −3 g/Lt. e comparison of drug degraded (if any) is measured against untreated sample at the same concentration. 
Results and Discussions
Method Development and
Validation. e HPLC procedure was optimized with a view to develop a stability indicating assay method. Different permutations and combinations, at different pH values ranging from pH 3.0 to pH 11.0 using various columns like Hypersil-BDS-C18, Symmetry C18, YMC-PACK C18, and YMC-PACK PRO, have been tried with different buffer salts such as ammonium acetate, potassium-di-hydrogen orthophosphate, dipotassium hydrogen orthophosphate, in combination with acetonitrile, methanol, and tetrahydrofuran. However, good resolution, less tailing, and high theoretical plates are obtained with Genesis column C18 50 × 4.6 cm. e mobile consists of 50 : 50 v/v acetonitrile and 0.1% orthophosphoric acid. To the 0.1% orthophosphoric acid 500 × 10 −6 L of triethyl amine is added for 500 mL of buffer. e �ow rate of the method is 0.6 mL/min. Diluent is prepared in the same way as mobile phase which consists of (50 : 50) methanol and 0.1% orthophosphoric acid without addition of tri-ethyl amine. e wavelength of detection is 294 nm. e column temperature is maintained at 25 ∘ C. At the reported �ow rate peak shape was excellent; however, increasing or decreasing the �ow rate increased the tailing factor and resulting in poor peak shape and also resolution between the drug and internal standard also decreased. Hence 0.6 mL/min was optimized �ow rate decreasing the consumption of the mobile phase, which in turn proves to be cost effective for long-term routine quality control analysis. ere was no interference in the drug and internal standard, from the blank. e peak-shape and symmetry were found to be good when the mobile-phase composition of 50 : 50 v/v was used with better resolution of the drug and internal standard.
Method Validation
3.2.1. System Suitability. e % RSD of the peak area and the retention time for both drug and internal standard are within the acceptable range (Table 1) . e efficiency of the column expressed as the number of USP theoretical plates for the six replicate injections was around 5527 ± 73 and the USP tailing factor was 1.25 ± 0.002 and the USP resolution between the internal standard and drug is 10.31 ± 0.08. Figures 2 and 3 represent the six replicate injections of the limit of detection and limit of quanti�cation. e method is found to be sensitive which can be determined from the data obtained from Tables 2 and 3 . e LOD concentration is 0.1 × 10 −3 g/Lt. e LOQ concentration is 0.2 × 10 −3 g/Lt.
Detection and Quantization Limits (Sensitivity).
3.2.3. Linearity. e calibration curve constructed was evaluated by its correlation coefficient. e peak area ratio of the drug and internal standard was linear, and the range is 2.01 and 50.20 μg/mL. e linearity was determined in three sets; the correlation coefficient ( 2 ) was consistently greater then 0.999 (Table 4) . From the data in Figure 4 and 3.2.�. Speci�city. Speci�city was determined from blank ( Figure 5 ), zero blank ( Figure 6 ), and sample containing both internal standard and drug ( Figure 7 ).
3.2.6. Stability. Stability studies were done for short-term stability up to 12 hrs, autosampler stability up to 24 hrs, and long-term stability up to 30 days at three different concentrations of low QC, medium QC, and high QC levels conditions and the mobile phase is stable up to 72 hrs (Table 6 ).
Stress
Testing. e stress studies involved heat, acid, light (UV), oxidation, and alkaline conditions. e drug is reasonably stable in all these conditions and no signi�cant degradation is observed. In certain conditions such alkaline conditions certain degraded peaks were observed accompanied with a reduction in the number of theoretical plates and increasing tailing and all these peaks were well resolved from drug and internal standard peaks (Tables 7 and 8 ). All these experimental and stress conditions were within the range of 90-110% for all stress conditions indicating the stability of the analytical method. e drug peaks obtained from all stress conditions were found to be homogeneous and pure. Hence this method is speci�c.
Robustness Study.
Robustness is the measure of method capacity to remain unaffected by deliberate small changes in the chromatographic conditions. e experimental conditions were deliberately altered to test evaluate the robustness of the method. e impact of �ow rate (0.6 ± 0.1), column temperature (25 ∘ C ± 5 ∘ C) changes, and effect of mobile-phase composition (±10%) was evaluated on the important system suitability factors such as retention time, theoretical plates, tailing factor, and resolution were studied. e experimental results were presented in Table 9 .
Application of the Method to Dosage
Forms. e HPLC method developed is sensitive and speci�c for the quantitative determination of quetiapine fumarate. Also the method is validated for different parameters, hence has been applied for the estimation of drug in pharmaceutical dosage forms. Quetiapine fumarate tablets of 200 mg and 300 mg strength from two different manufacturers were evaluated for the amount of quetiapine fumarate. e amount of quetiapine fumarate in tablet 1 is 98.49 ± 0.36 and tablet 2 is 98.59 ± 0.35 (Table 10 ). None of the tablets ingredients interfere with the analytic peak. e spectrum of quetiapine fumarate extracted from the tablets was matching with that of standard quetiapine fumarate showing the purity of peak of quetiapine fumarate in the tablets.
Conclusion
A rapid sensitive and speci�c method for the determination of quetiapine fumarate in the pharmaceutical formulations has been developed using lamotrogine as the internal standard. e method gave accurate and precise results in the concentration range from 2.01 to 49.500 × 10 −3 g/Lt. e mobile-phase composition is 50 : 50 acetonitrile: 0.1% orthophosphoric acid, at the �ow rate of 0.6 mL/min. e retention times of internal standard and the drug are 1.45 ± 0.05 and 3.6 ± 0.05, respectively. e column is a 50 × 4.6 mm C18 column with the particle size of 3 μm. Quetiapine fumarate is tested for the stress conditions like photostability, acid stability, alkaline, oxidation, and thermal conditions for the 24 Hrs. Quetiapine fumarate is stable and did not show any signs of degradation under stress conditions.
Abbreviations
Rs:
USP resolution 8 Journal of Chemistry : Retention time along the baseline from the point of injection to the perpendicular dropped from the maximum of the peak corresponding to the analyte : Width of the peak at half the height 0.5 : Width of the peak at 1/20 of peak height : Distance between perpendicular dropped from peak maximum to the leading edge of the peak at 1/20 of peak height.
